OSE has a well-balanced R&D pipeline in terms of technology and asset stage (from discovery to Phase III). At the American Association of Cancer Research (AACR) Virtual Annual Meeting II in late June, OSE announced new data from its two more interesting preclinical programmes. C-type lectin receptor (CLEC-1) is a newly disclosed myeloid checkpoint target that tumour cells use to inhibit myeloid cells phagocytosis, a ‘don’t eat me’ signal. Anti-CLEC-1 antibodies restored
08 Jul 2020
OSE Immunotherapeutics - Encouraging data from novel preclinical projects
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - Encouraging data from novel preclinical projects
OSE Immunotherapeutics SA (OSE:PAR) | 0 0 0.0%
- Published:
08 Jul 2020 -
Author:
Dr Jonas Peciulis -
Pages:
9
OSE has a well-balanced R&D pipeline in terms of technology and asset stage (from discovery to Phase III). At the American Association of Cancer Research (AACR) Virtual Annual Meeting II in late June, OSE announced new data from its two more interesting preclinical programmes. C-type lectin receptor (CLEC-1) is a newly disclosed myeloid checkpoint target that tumour cells use to inhibit myeloid cells phagocytosis, a ‘don’t eat me’ signal. Anti-CLEC-1 antibodies restored